Terms: = Adult Hodgkin lymphoma AND BCL2, Bcl-2, 596, ENSG00000171791 AND Clinical Outcome
37 results:
1. bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell lymphoma.
Luanpitpong S; Janan M; Yosudjai J; Poohadsuan J; Chanvorachote P; Issaragrisil S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430955
[TBL] [Abstract] [Full Text] [Related]
2. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.
Maes A; Maes K; Vlummens P; De Raeve H; Devin J; Szablewski V; De Veirman K; Menu E; Moreaux J; Vanderkerken K; De Bruyne E
Blood Cancer J; 2019 Nov; 9(12):87. PubMed ID: 31740676
[TBL] [Abstract] [Full Text] [Related]
3. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, bcl-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract] [Full Text] [Related]
4. C-MYC and bcl2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
Akkaya B; Salim O; Akkaya H; Ozcan M; Yucel OK; Erdem R; Iltar U; Undar L
Indian J Pathol Microbiol; 2016; 59(1):41-6. PubMed ID: 26960633
[TBL] [Abstract] [Full Text] [Related]
5. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract] [Full Text] [Related]
6. Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.
Bellas C; García D; Vicente Y; Kilany L; Abraira V; Navarro B; Provencio M; Martín P
PLoS One; 2014; 9(6):e98169. PubMed ID: 24887414
[TBL] [Abstract] [Full Text] [Related]
7. Intranodular clusters of activated cells with T follicular helper phenotype in nodular lymphocyte predominant hodgkin lymphoma: a pilot study of 32 cases from Finland.
Nathwani BN; Vornanen M; Winkelmann R; Kansal R; Doering C; Hartmann S; Hansmann ML
Hum Pathol; 2013 Sep; 44(9):1737-46. PubMed ID: 23684509
[TBL] [Abstract] [Full Text] [Related]
8. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract] [Full Text] [Related]
9. New therapeutic targets and drugs in non-hodgkin's lymphoma.
Sawas A; Diefenbach C; O'Connor OA
Curr Opin Hematol; 2011 Jul; 18(4):280-7. PubMed ID: 21654386
[TBL] [Abstract] [Full Text] [Related]
10. Improved demonstration of immunohistochemical prognostic markers for survival in follicular lymphoma cells.
Camacho FI; Bellas C; Corbacho C; Caleo A; Arranz-Sáez R; Cannata J; Menárguez J; Sánchez-Verde L; González-Camacho L; Pérez-Martín ME; Martínez-González MA; Alvaro T; Mollejo M; Ruíz-Marcellán C; Montalbán C; Piris MA
Mod Pathol; 2011 May; 24(5):698-707. PubMed ID: 21240256
[TBL] [Abstract] [Full Text] [Related]
11. clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL).
Markovic O; Marisavljevic D; Cemerikic V; Perunicic M; Savic S; Filipovic B; Mihaljevic B
Eur J Haematol; 2011 Mar; 86(3):246-55. PubMed ID: 21198858
[TBL] [Abstract] [Full Text] [Related]
12. Autophagy-active beclin-1 correlates with favourable clinical outcome in non-hodgkin lymphomas.
Nicotra G; Mercalli F; Peracchio C; Castino R; Follo C; Valente G; Isidoro C
Mod Pathol; 2010 Jul; 23(7):937-50. PubMed ID: 20473282
[TBL] [Abstract] [Full Text] [Related]
13. bcl2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
[TBL] [Abstract] [Full Text] [Related]
14. Role of immunoexpression of nitric oxide synthases by hodgkin and Reed-Sternberg cells on apoptosis deregulation and on clinical outcome of classical hodgkin lymphoma.
Campos AH; Aldred VL; Ribeiro KC; Vassallo J; Soares FA
Mol Cell Biochem; 2009 Jan; 321(1-2):95-102. PubMed ID: 18830569
[TBL] [Abstract] [Full Text] [Related]
15. The impact of high-dose sodium selenite therapy on bcl-2 expression in adult non-hodgkin's lymphoma patients: correlation with response and survival.
Asfour IA; Fayek M; Raouf S; Soliman M; Hegab HM; El-Desoky H; Saleh R; Moussa MA
Biol Trace Elem Res; 2007; 120(1-3):1-10. PubMed ID: 17916949
[TBL] [Abstract] [Full Text] [Related]
16. The expression of Ki-67 and bcl-2 in hodgkin's lymphoma: correlation with the International Prognostic Score and bulky disease: a study by the Serbian lymphoma Study Group (SLG).
Jakovic LR; Mihaljevic BS; Jovanovic MD; Bogdanovic AD; Martinovic VM; Kravic TK; Bumbasirevic VZ;
Med Oncol; 2007; 24(1):45-53. PubMed ID: 17673811
[TBL] [Abstract] [Full Text] [Related]
17. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-hodgkin's lymphoma patients treated with sequential CHOP and rituximab.
Carlotti E; Palumbo GA; Oldani E; Tibullo D; Salmoiraghi S; Rossi A; Golay J; Pulsoni A; Foà R; Rambaldi A
Haematologica; 2007 Aug; 92(8):1127-30. PubMed ID: 17650444
[TBL] [Abstract] [Full Text] [Related]
18. [Clinicopathologic features, prognosis and etiology of primary non-hodgkin lymphoma of bone].
Zhou ZY; Shi QL; Zhou XJ; Lan JY; Wang JD; Huang WB; Chen JY; Ma HH; Zhou HB
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):90-3. PubMed ID: 17493381
[TBL] [Abstract] [Full Text] [Related]
19. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Kaplan LD; Lee JY; Ambinder RF; Sparano JA; Cesarman E; Chadburn A; Levine AM; Scadden DT
Blood; 2005 Sep; 106(5):1538-43. PubMed ID: 15914552
[TBL] [Abstract] [Full Text] [Related]
20. Quantitative PCR of bone marrow bcl2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-hodgkin lymphoma.
Rambaldi A; Carlotti E; Oldani E; Della Starza I; Baccarani M; Cortelazzo S; Lauria F; Arcaini L; Morra E; Pulsoni A; Rigacci L; Rupolo M; Zaja F; Zinzani PL; Barbui T; Foa R
Blood; 2005 May; 105(9):3428-33. PubMed ID: 15637137
[TBL] [Abstract] [Full Text] [Related]
[Next]
